Physician profile
James P Scherman
NPI 1548574775
$2,934.62
in general payments reported to CMS, 2019-2025
14 companies · $476 in 2025
The $476 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $179 · 2021: $549 · 2022: $507 · 2023: $442 · 2024: $268 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $755.55 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $498.87 | 2019-2025 | Cvi Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $458.33 | 2019-2021 | |
| Alcon Vision LLC | $393.71 | 2019-2023 | Precision 1 |
| Abbvie INC. | $248.02 | 2022-2025 | |
| Allergan, INC. | $199.17 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $185.03 | 2019-2025 | Cequa |
| Menicon America INC | $47.51 | 2019 | |
| Oyster Point Pharma, INC. | $37.86 | 2022 | |
| Astellas Pharma US INC | $35.05 | 2024-2025 | Izervay |
| Dompe US, INC. | $26.83 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $20.59 | 2023 | Acuvue |
| Eyevance Pharmaceuticals LLC | $15.96 | 2019 | |
| Shire North American Group INC | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Scherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.